Why FOXO3?
Why FOXO3?
FOXO3 is a Master Orchestrator
FOXO3 is a Master Orchestrator
FOXO3 is a Master Orchestrator
Modulating FOXO3 is a promising strategy for treating age-related diseases because this protein is crucial in regulating cellular homeostasis, multi-organ responses to diverse forms of stress, and human health.
Traditional drug development often focuses on single proteins or signalling pathways, achieving limited success for complex and multifactorial disorders.
By targeting the transcription factor FOXO3, we can tap into a master orchestrator that influences multiple biological processes, potentially eliciting greater therapeutic effects and improving health span by combating age-related pathologies such as fibrotic and cardiovascular diseases.
Modulating FOXO3 is a promising strategy for treating age-related diseases because this protein is crucial in regulating cellular homeostasis, multi-organ responses to diverse forms of stress, and human health.
Traditional drug development often focuses on single proteins or signalling pathways, achieving limited success for complex and multifactorial disorders.
By targeting the transcription factor FOXO3, we can tap into a master orchestrator that influences multiple biological processes, potentially eliciting greater therapeutic effects and improving health span by combating age-related pathologies such as fibrotic and cardiovascular diseases.
How we do it
How we do it
Activating Cellular Health at its Core
Activating Cellular Health at its Core
Traditionally, transcription factors such as FOXO3 have been deemed undruggable targets. We circunvent this misconsived limintation through our proprietary FOXO activator finder (F.act Finder) Platform. With F.act Finder, we identify and develop small molecules that activate FOXO3, and through those we harness some of FOXO3’s physiological activities..
By boosting FOXO3 activity, we aim to slow disease progression and restore stress-response capacity, pioneering a new era of therapies designed to challenge aging at its source.
Our platform builds upon pioneering work from our scientific co-founder, Prof. Wolfgang Link, and relies on a combination of phenotypic screening, unbiased assessments of FOXO3 specificity, and multiple built-in safety and counter-screening measurements.
Traditionally, transcription factors such as FOXO3 have been deemed undruggable targets. We circunvent this misconsived limintation through our proprietary FOXO activator finder (F.act Finder) Platform. With F.act Finder, we identify and develop small molecules that activate FOXO3, and through those we harness some of FOXO3’s physiological activities..
By boosting FOXO3 activity, we aim to slow disease progression and restore stress-response capacity, pioneering a new era of therapies designed to challenge aging at its source.
Our platform builds upon pioneering work from our scientific co-founder, Prof. Wolfgang Link, and relies on a combination of phenotypic screening, unbiased assessments of FOXO3 specificity, and multiple built-in safety and counter-screening measurements.
Traditionally, transcription factors such as FOXO3 have been deemed undruggable targets. We circunvent this misconsived limintation through our proprietary FOXO activator finder (F.act Finder) Platform. With F.act Finder, we identify and develop small molecules that activate FOXO3, and through those we harness some of FOXO3’s physiological activities..
By boosting FOXO3 activity, we aim to slow disease progression and restore stress-response capacity, pioneering a new era of therapies designed to challenge aging at its source.
Our platform builds upon pioneering work from our scientific co-founder, Prof. Wolfgang Link, and relies on a combination of phenotypic screening, unbiased assessments of FOXO3 specificity, and multiple built-in safety and counter-screening measurements.
Our Pipeline
Our Pipeline
Drug Discovery & Asset Development
Drug Discovery & Asset Development
Our lead series has shown robust anti-fibrotic effects in preclinical studies and is currently being developed for Idiopathic Pulmonary Fibrosis (IPF) — a severe, life-limiting lung disease.
In parallel, we are advancing a broader pipeline of FOXO3-activating molecules for additional indications where aging and chronic stress are key drivers of pathology.
Our lead series has shown robust anti-fibrotic effects in preclinical studies and is currently being developed for Idiopathic Pulmonary Fibrosis (IPF) — a severe, life-limiting lung disease. This program is just the beginning.
We are also advancing a broader pipeline of FOXO3-targeting molecules for additional indications where aging and chronic stress are key drivers of pathology.
Discover How Advanced Science Can Transform Health
Get in touch
Discover How Advanced Science Can Transform Health
Get in touch
Discover How Advanced Science Can Transform Health
Get in touch
Discover How Advanced Science Can Transform Health
Get in touch
